Other Vaccines - Chile

Chile

Highlights

In Chile, the projected revenue for the Other Vaccines market is set to reach US$112.90m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 10.26%, leading to a market volume of US$184.00m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$24.73bn in 2024.
Chile has seen a growing demand for other vaccines, driven by the government's focus on expanding the country's immunization program.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Chile has been steadily growing in recent years, driven by a combination of factors.

Customer preferences: Chilean consumers have become increasingly health-conscious, leading to a greater demand for preventative healthcare measures such as vaccines. Additionally, the government has implemented various vaccination campaigns to increase awareness and accessibility.

Trends in the market: One of the main trends in the Other Vaccines market in Chile has been the rise of private healthcare providers. With the public healthcare system struggling to meet demand, many consumers are turning to private clinics for vaccinations. This has led to increased competition in the market and a greater focus on customer service and convenience.Another trend has been the growing popularity of travel vaccines. As more Chileans travel abroad for work or leisure, there has been a corresponding increase in demand for vaccines that protect against diseases prevalent in other countries.

Local special circumstances: Chile's location in South America has made it particularly vulnerable to outbreaks of diseases such as yellow fever and dengue fever. This has led to a greater emphasis on preventative measures such as vaccination.

Underlying macroeconomic factors: Chile's strong economy has led to increased healthcare spending, which has in turn driven growth in the Other Vaccines market. Additionally, the country's aging population has created a greater need for preventative healthcare measures, including vaccinations. Finally, the government's focus on healthcare reform has led to increased investment in the sector, benefiting both public and private providers.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.